BC Innovations | Jun 28, 2018
Translation in Brief

Synchronous signaling

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...
BC Innovations | May 9, 2018
Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
BC Week In Review | Apr 27, 2018
Clinical News

Regenerative Patch Technologies' CPCB-RPE1 successfully implanted in AMD patients

Top-line data from the Phase I portion of a Phase I/IIa trial showed that CPCB-RPE1 from Regenerative Patch Technologies Inc. (Glendale, Calif.) was successfully implanted into an eye of four of five patients with non-neovascular...
BC Extra | Mar 26, 2018
Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...
BC Innovations | Mar 26, 2018
Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
BC Week In Review | Jan 19, 2018
Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
BC Innovations | Jan 4, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
BC Week In Review | Aug 28, 2017
Clinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported preclinical data showing that prostate cancer candidate GNE-049 blocked expression of key proliferative genes and reduced tumor growth. In patient-derived xenograft mouse models of...
BC Extra | Aug 23, 2017
Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein ( CREBBP ; CBP) as an epigenetic strategy for treating prostate cancer is mounting. In a paper published in Cancer...
BC Innovations | Apr 7, 2017
Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
Items per page:
1 - 10 of 317